• Advised on the design of innovative pay for health outcomes contracting agreements with health insurers and biopharma companies, helped negotiate agreements  
  • Written company positions for external use on pricing, price increases, investment in research, clinical trials, genetic testing, cost sharing. Guided multiple CEO's for external engagements and leadership roles in trade associations. 
  • Guided the establishment pricing and rebates for medicines in oncology, rare disease, cardiovascular disease and infectious disease considering health value, affordability and access through public and private health insurance. 
  • Calculated the financial impact of major legislative change to corporate revenue and income including the Affordable Care Act, Medicare Part D, Medicaid Preferred Drug Lists and China's Quality Consistency Evaluation 
  • Helped design patient assistance programs for pharmaceuticals for both insured and uninsured people 
  • Advised and supported leaders for Congressional testimony or discussions with members of congress and staff about health policy. Prepared companies for state and federal investigation on pricing and marketing.